Clinical Trial: Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07392658) titled 'Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.' on Nov. 24, 2025.

Brief Summary: To assess safety and efficacy of amivantamab plus monochemotherapy in terms of ORR, PFS and OS in subjects with EGFR exon20 insertion mutations metastatic non-small cell lung cancer unfit for platinum-based chemotherapy.

Study Start Date: Dec. 02, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic NSCLC - Non-Small Cell Lung Cancer

Intervention: DRUG: Amivantamab

Subcutaneous amivantamab at the dose of 1600 mg (2240 mg, >=80 kg) on cycle 1 day 1, than at the dose of 240...